Search Within

Mrinal M Gounder

Formats
  1. Meeting Abstract (119)
  2. Journal Article (100)
  3. Review (5)
  4. Guidelines (2)
  5. Research Letter (2)
  6. Book Section (1)
  7. Correspondence (1)
  8. Editorial (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (232)
  2. Sarcoma Service (232)
  3. Solid Tumor Oncology Division (232)
  4. GSK Faculty (89)
  5. Hematologic Malignancies, Division of (87)
  6. Tow Center for Developmental Oncology (TCDO) (85)

More Groups

People
  1. William Tap (80)
  2. Mary Keohan (75)
  3. Sandra D'Angelo (75)
  4. Mark Dickson (72)
  5. Ping Chi (59)
  6. Li-Xuan Qin (53)

More People

Years
  1. 2025 (9)
  2. 2024 (17)
  3. 2023 (21)
  4. 2022 (36)
  5. 2021 (16)
  6. 2020 (25)

More Years

Publications
  1. Journal of Clinical Oncology (86)
  2. Annals of Oncology (24)
  3. Clinical Cancer Research (20)
  4. Cancer (7)
  5. The Oncologist (6)
  6. European Journal of Cancer (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (88)
  2. Oxford University Press (30)
  3. American Association for Cancer Research (29)
  4. Springer (14)
  5. Elsevier Inc. (11)
  6. Nature Publishing Group (10)

More Publishers

Results (232)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950)
    Meeting Abstract

    Jones, R. L.; Blay, J. Y.; Agulnik, M.; Chugh, R.; Mir, O.; Italiano, A.; Thomas, D.; Gupta, A.; Jahan, T.; Cote, G.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950)
    Meeting Abstract

    Daigle, S.; Stacchiotti, S.; Schöffski, P.; Villalobos, V.; Cote, G.; Chugh, R.; Chen, T. W. W.; Jahan, T.; Loggers, E. T.; Italiano, A.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Sorafenib for advanced and refractory desmoid tumors
    Journal Article

    Gounder, M. M.; Mahoney, M. R.; Van Tine, B. A.; Ravi, V.; Attia, S.; Deshpande, H. A.; Gupta, A. A.; Milhem, M. M.; Conry, R. M.; Movva, S.; more...
    New England Journal of Medicine (2018)

    Fulltext@MSK | Save
  • Reply to E. Younger et al
    Journal Article

    Atkinson, T. M.; Gounder, M. M.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials
    Journal Article

    Yokota, T.; Bendell, J.; Lorusso, P.; Tsushima, T.; Desai, V.; Kenmotsu, H.; Watanabe, J.; Ono, A.; Murugesan, B.; Silva, J.; more...
    British Journal of Cancer (2018)

    Fulltext@MSK | Save
  • Trametinib in histiocytic sarcoma with an activating MAP2K1 (MEK1) mutation - To the editor
    Journal Article

    Gounder, M. M.; Solit, D. B.; Tap, W. D.
    New England Journal of Medicine (2018)

    Fulltext@MSK | Save
  • Pathogenic SMARCA4 mutations in head and neck and thyroid carcinomas are rare
    Meeting Abstract

    Arias-Stella, J. A.; Rana, S.; Gounder, M. M.; Ladanyi, M.; Dogan, S.
    Modern Pathology (2018)

    Fulltext@MSK | Save
  • Genetic and histologic spectrum of SMARCB1-deficient carcinomas of the head and neck including sinonasal tract, thyroid and skin
    Meeting Abstract

    Cotzia, P.; Ptashkin, R.; Gounder, M. M.; Pfister, D. G.; Berger, M. F.; Ladanyi, M.; Ghossein, R.; Antonescu, C. R.; Dogan, S.
    Modern Pathology (2018)

    Fulltext@MSK | Save
  • Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)+ metastatic breast cancer (MBC)
    Meeting Abstract

    Gucalp, A.; Edelweiss, M.; Patil, S.; Gounder, M. M.; Feigin, K. N.; Corben, A.; Arumov, A.; Traina, T. A.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Locally aggressive connective tissue tumors
    Journal Article

    Gounder, M. M.; Thomas, D. M.; Tap, W. D.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save